Printer Friendly

Verona Pharma updates on clinical development.

M2 EQUITYBITES-February 13, 2018-Verona Pharma updates on clinical development


Verona Pharma plc (LON: WRP) has brought forward the timing for top-line data readouts for its ongoing clinical trials in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) following clinical development updates, the company revealed on Tuesday.

The Phase 2b clinical trial of nebulised RPL554 for COPD maintenance treatment is now expected to report top-line data in the second quarter of 2018, brought forward from mid-2018.

The four-week, double-blind, placebo-controlled, parallel group Phase 2b study involved around 400 patients with moderate-to-severe COPD and took place at numerous sites across Europe. The aim of the study was to investigate the efficacy, safety and dose-response of nebulised RPL554.

Verona Pharma has also brought forward reporting of top-line data from the Phase 2a pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial of RPL54 for CF to the late first quarter of 2018, from the first half of 2018.

The double-blind, placebo-controlled, cross-over Phase 2a study is evaluating the PK and PD profile and tolerability of a single nebulised dose of RPL554 and the effect on lung function in 10 patients with CF.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Clinical report
Date:Feb 13, 2018
Previous Article:Live Nation Acquires Songkick Assets as Companies Settle Litigation.
Next Article:Erytech names triple negative breast cancer as next indication for eryaspase.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters